Health economic assessment of Jemperli in endometrial cancer

TLV

11 February 2022 - TLV has produced a health economic assessment for the regions for the drug Jemperli (dostarlimab) which is intended for patients with endometrial cancer.

Jemperli has been investigated in a study that is still on-going. It is uncertain what effect the drug has on time to relapse and survival, respectively.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder